Good morning :)
Divi's Laboratories Ltd

Divi's Laboratories Ltd

DIVISLAB Share Price

NSE
₹11,080.003.16% (-362.00)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max
SIP

With a market cap of ₹2,94,139 cr, stock is ranked 32

Stock is 1.76x as volatile as Nifty

DIVISLAB Stock Scorecard

Performance

Avg

Price return has been average, nothing exciting

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Avg

The stock is overpriced but is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

With a market cap of ₹2,94,139 cr, stock is ranked 32

Stock is 1.76x as volatile as Nifty

DIVISLAB Performance & Key Metrics

DIVISLAB Performance & Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
87.4617.550.27%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
45.156.040.48%

DIVISLAB Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 
72%
Analysts have suggested that investors can buy this stock

from 25 analysts

Price Upside

Earnings Growth

Rev. Growth

See Detailed Forecast

DIVISLAB Company Profile

Divi's Laboratories Limited is engaged in manufacturing and sale of active pharmaceutical ingredients (APIs) and Intermediates. Its products include Generic APIs, Intermediates, Peptide Building Blocks and Carotenoids.

DIVISLAB Similar Stocks (Peers)

Compare with peers Compare with peers 

DIVISLAB Similar Stocks (Peers)

Compare with peers Compare with peers 
PE Ratio
47.20
47.20
1Y Return
32.35%
32.35%
Buy Reco %
75.00
75.00
PE Ratio
50.61
50.61
1Y Return
35.36%
35.36%
Buy Reco %
0.00
0.00
PE Ratio
28.07
28.07
1Y Return
21.42%
21.42%
Buy Reco %
0.00
0.00
PE Ratio
22.02
22.02
1Y Return
44.70%
44.70%
Buy Reco %
0.00
0.00
PE Ratio
41.71
41.71
1Y Return
36.56%
36.56%
Buy Reco %
0.00
0.00
Compare with Peers

DIVISLAB Sentiment Analysis

DIVISLAB Sentiment Analysis

New
Crisp summary & key insights to decode earnings calls instantly

DIVISLAB Stock Summary · August 2026

Management said the quarter combined solid growth with near-term margin pressure as the business shifted further toward custom synthesis and continued to invest heavily for future capacity. Consolidated total income rose to ₹3,144 crores from ₹2,529 crores year over year, while profit before tax increased to ₹1,180 crores from ₹733 crores, even as a forex gain of ₹39 crores last year became a ₹7 crore loss this quarter. Custom synthesis accounted for 60% of revenue versus 40% for generics, and standalone revenue grew 10% on a constant currency basis, but generic pricing remained under competitive pressure and higher raw material and solvent costs were only partially passed through. Management said the three major capex programs are nearing completion, with ₹451 crores capitalized in the quarter and ₹2,034 crores still in capital work in progress, while validation and regulatory timing continue to govern commercialization. Peptides were highlighted as a strategic focus, and management reiterated confidence in double-digit revenue growth for the year, while expecting quarterly results to remain lumpy.

DIVISLAB Stock Growth Drivers
DIVISLAB Stock Growth Drivers
6
  • Operational Resilience Through Backward Integration and Supply Assurance

    The company has strengthened the resilience of its manufacturing network through in-house production of key

  • Capacity Expansion and Network Modernization for Future Growth

    The company is actively building future capability through major capex completion, validation work, and phased

DIVISLAB Stock Challenges
DIVISLAB Stock Challenges
5
  • Generic pricing pressure remains unresolved

    The generic business is still operating under competitive pricing pressure, with volumes broadly stable but

  • Input cost inflation and solvent volatility are pressuring margins

    Raw material costs have risen across multiple inputs, with solvents highlighted as a recurring source

DIVISLAB Forecast

DIVISLAB Forecasts

Price

Revenue

Earnings

DIVISLAB

DIVISLAB

Income

Balance Sheet

Cash Flow

DIVISLAB Income Statement

DIVISLAB Income Statement

Loading...

Quarterjun 2024sep 2024dec 2024mar 2025jun 2025sep 2025dec 2025mar 2026jun 2026sep 2026
Total Revenue2,197.002,444.002,401.002,671.002,529.002,860.002,692.002,986.003,144.003,770.00
Operating & Other expensessubtract1,496.001,622.001,576.001,699.001,681.001,827.001,788.001,897.001,825.002,110.00
Depreciation/Amortizationsubtract97.0099.0099.00107.00112.00113.00118.00120.00133.00142.00
Interest & Other Itemssubtract0.001.000.001.003.008.006.006.006.0013.00
Taxes & Other Itemssubtract174.00212.00137.00202.00188.00223.00197.00212.00278.00378.00
EPS16.2019.2022.2024.9320.4925.9721.9828.3133.9542.49

DIVISLAB Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2026FY 2026

Annual report

PDF
FY 2025FY 2025

Annual report

PDF
FY 2024FY 2024

Annual report

PDF
FY 2023FY 2023

Annual report

PDF
FY 2022FY 2022

Annual report

PDF
FY 2021FY 2021

Annual report

PDF
FY 2020FY 2020

Annual report

PDF
FY 2019FY 2019

Annual report

PDF
FY 2018FY 2018

Annual report

PDF
 

DIVISLAB Stock Peers

DIVISLAB Past Performance & Peer Comparison

DIVISLAB Past Performance & Peer Comparison

Comparing 3 stocks from 
Health CareLabs & Life Sciences Services

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Divi's Laboratories Ltd112.1417.550.27%
Syngene International Ltd47.203.670.28%
Aarti Pharmalabs Ltd50.614.210.35%
Vimta Labs Ltd28.074.840.40%
ScreenerCompare valuation on Screener

DIVISLAB Stock Price Comparison

Compare DIVISLAB with any stock or ETF
Compare DIVISLAB with any stock or ETF
DIVISLAB
Loading...

DIVISLAB Holdings

DIVISLAB Shareholdings

DIVISLAB Promoter Holdings Trend

DIVISLAB Promoter Holdings Trend

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

DIVISLAB Institutional Holdings Trend

DIVISLAB Institutional Holdings Trend

Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

DIVISLAB Shareholding Pattern

DIVISLAB Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding51.88%14.66%4.50%20.38%8.58%

Dec 2025

Mar 2026

Jun 2026

Sep 2026

DIVISLAB Shareholding History

DIVISLAB Shareholding History

JunSepDec '25MarJunSep19.74%19.39%20.08%20.29%20.20%20.38%

Mutual Funds Invested in DIVISLAB

Mutual Funds Invested in DIVISLAB

No mutual funds holding trends are available

Top 5 Mutual Funds holding Divi's Laboratories Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
0.6543%3.79%0.84%6/61 (+5)
0.5474%1.94%-0.17%16/137 (-2)
0.5248%1.44%0.07%52/94 (0)

Compare 3-month MF holding change on Screener

DIVISLAB Insider Trades & Bulk Stock Deals

DIVISLAB Insider Trades & Bulk Stock Deals

Loading...

smallcases containing DIVISLAB stock

smallcases containing DIVISLAB stock

Looks like this stock is not in any smallcase yet.

DIVISLAB Events

DIVISLAB Events

DIVISLAB Dividend Trend

No Dividend Cuts
Dividends are the portion of earnings that a company distributes to all its shareholders every year

DIVISLAB has increased or maintained dividend levels over the last 5 years

Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation

Current dividend yield is 0.27%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹2.71 every year

Dividends

Corp. Actions

Announcements

Legal Orders

DIVISLAB Dividend Trend

No Dividend Cuts
Dividends are the portion of earnings that a company distributes to all its shareholders every year

DIVISLAB has increased or maintained dividend levels over the last 5 years

Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation

Current dividend yield is 0.27%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹2.71 every year

DIVISLAB Upcoming Dividends

DIVISLAB Upcoming Dividends

No upcoming dividends are available

DIVISLAB Past Dividends

DIVISLAB Past Dividends

Cash Dividend

Ex DateEx DateJul 24, 2026

Final
Final | Div/Share: ₹30.00

Dividend/Share

₹30.00

Ex DateEx Date

Jul 24, 2026

Cash Dividend

Ex DateEx DateJul 25, 2025

Final
Final | Div/Share: ₹30.00

Dividend/Share

₹30.00

Ex DateEx Date

Jul 25, 2025

Cash Dividend

Ex DateEx DateAug 2, 2024

Final
Final | Div/Share: ₹30.00

Dividend/Share

₹30.00

Ex DateEx Date

Aug 2, 2024

Cash Dividend

Ex DateEx DateAug 11, 2023

Final
Final | Div/Share: ₹30.00

Dividend/Share

₹30.00

Ex DateEx Date

Aug 11, 2023

Cash Dividend

Ex DateEx DateAug 11, 2022

Final
Final | Div/Share: ₹30.00

Dividend/Share

₹30.00

Ex DateEx Date

Aug 11, 2022

DIVISLAB Stock News & Opinions

DIVISLAB Stock News & Opinions

Earnings
Earnings
Divis Laboratories Ltd consolidated sales up 19.35% on year in Q2FY2027, net profit surged by 24.94%

Divis Laboratories Ltd share price inched up 1.53% to Rs 10305.0 after the company's net profit jumped 24.94% to Rs 1127.0 crore, while revenue from operations edged up 19.35% to Rs 3676.0 crore in Q2FY27 over Q2FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.82 lakh crore, gaining 5.81%. It has improved by 2.89% over last one week and gained upto 3.43% in last one month while the market capitalization of Divis Laboratories Ltd has marginally improved by 6.07% and 24.93% in the same period respectively. Profit before tax (PBT) of Divis Laboratories Ltd stood at Rs 1505.0 crore in Q2 FY27, surging by 65.02% year-on-year, and expanding by 27.54% quarter-on-quarter. EBITDA came in at Rs 1472 crore, rallying 98.12% YoY and jumping 23.59% sequentially. Total expenses advancing by 15.02% to Rs 2252.0 crore in Q2FY27 over Q2FY26. During the quarter, cost of materials consumed stood at Rs 1812.0 crore, soaring by 20.56% YoY, while employee benefits expense was at Rs 444.0 crore, rising by 8.82% YoY. For FY26, revenue from operations advanced 12.82% to Rs 10560.0 crore, while net profit expanded by 17.21% to Rs 2568.0 crore, compared to previous FY. EBITDA witnessed a strong improvement of 267600% to Rs 2934.0 crore, and PBT registered a growth of 16.19% to Rs 3388.0 crore compared to previous FY. The company's consolidated net cash flow from operating activities stood at Rs 2738.0 crore in FY26, as against Rs 1653.0 crore in FY25. Divis Laboratories Ltd rallied 49.64% in last one year, significantly outperforming the benchmark BSE Sensex which has slipped by 2.74% during the same period.

1 week agoCapital Market - Live
Spotlight
Spotlight
Divis Laboratories Ltd spurts 1.52%, up for fifth straight session

Divis Laboratories Ltd is up for a fifth straight session today. The stock is quoting at Rs 9811, up 1.52% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.72% on the day, quoting at 23102.8. The Sensex is at 74677.67, up 0.71%. Divis Laboratories Ltd has gained around 6.08% in last one month. Meanwhile, Nifty Pharma index of which Divis Laboratories Ltd is a constituent, has gained around 3.43% in last one month and is currently quoting at 26710.8, up 1.88% on the day. The volume in the stock stood at 6.02 lakh shares today, compared to the daily average of 5.93 lakh shares in last one month. The benchmark November futures contract for the stock is quoting at Rs 9862, up 1.3% on the day. Divis Laboratories Ltd is up 45.61% in last one year as compared to a 10.18% slide in NIFTY and a 22.72% slide in the Nifty Pharma index.The PE of the stock is 85.56 based on TTM earnings ending June 26.

2 weeks agoCapital Market - Live
Spotlight
Spotlight
Divis Laboratories Ltd rises for third straight session

Divis Laboratories Ltd is up for a third straight session today. The stock is quoting at Rs 9616.5, up 1.17% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.19% on the day, quoting at 22705.75. The Sensex is at 73339.6, down 0.35%. Divis Laboratories Ltd has gained around 1.97% in last one month. Meanwhile, Nifty Pharma index of which Divis Laboratories Ltd is a constituent, has gained around 1.54% in last one month and is currently quoting at 26267.25, up 0.96% on the day. The volume in the stock stood at 5.07 lakh shares today, compared to the daily average of 5.95 lakh shares in last one month. The benchmark November futures contract for the stock is quoting at Rs 9663, up 1.79% on the day. Divis Laboratories Ltd is up 47.67% in last one year as compared to a 12.85% slide in NIFTY and a 18.23% slide in the Nifty Pharma index.The PE of the stock is 83.99 based on TTM earnings ending June 26.

2 weeks agoCapital Market - Live
Corporate
Corporate
Divi's Laboratories to review financial results at a board meeting November 7, 2026

Divi's Laboratories Limited will hold a board meeting on Saturday, November 07, 2026, to consider and approve unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, the company said in a filing with the National Stock Exchange of India Limited and BSE Limited. The trading window for the company's securities has been closed from October 01, 2026, and will remain so until November 09, 2026, following the declaration of the financial results.

3 weeks agoCapital Market - Live
Spotlight
Spotlight
Divis Laboratories Ltd drops for fifth straight session

Divis Laboratories Ltd fell for a fifth straight session today. The stock is quoting at Rs 9175.5, down 0.79% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is up around 0.25% on the day, quoting at 22478.35. The Sensex is at 72078.38, up 0.23%.Divis Laboratories Ltd has eased around 1.5% in last one month.Meanwhile, Nifty Pharma index of which Divis Laboratories Ltd is a constituent, has eased around 2.14% in last one month and is currently quoting at 26311.55, down 0.79% on the day. The volume in the stock stood at 2.71 lakh shares today, compared to the daily average of 5.21 lakh shares in last one month. The benchmark October futures contract for the stock is quoting at Rs 9226, down 0.44% on the day. Divis Laboratories Ltd jumped 57.48% in last one year as compared to a 10.37% slide in NIFTY and a 19.85% spurt in the Nifty Pharma index.The PE of the stock is 82.36 based on TTM earnings ending June 26.

1 month agoCapital Market - Live
Corporate
Corporate
Divi's Laboratories closes securities trading window ahead of financial results declaration

Divi’s Laboratories Limited informed the National Stock Exchange of India Limited and the BSE Limited that the trading window for dealing in the company's securities will be closed from October 01, 2026, until 48 hours after the declaration of unaudited financial results for the quarter and half year ending September 30, 2026.

1 month agoCapital Market - Live
Spotlight
Spotlight
Divis Laboratories Ltd down for fifth straight session

Divis Laboratories Ltd is down for a fifth straight session today. The stock is quoting at Rs 9108.5, down 0.97% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is up around 0.65% on the day, quoting at 23269.55. The Sensex is at 74411.94, up 0.55%.Divis Laboratories Ltd has added around 7.39% in last one month.Meanwhile, Nifty Pharma index of which Divis Laboratories Ltd is a constituent, has eased around 0.81% in last one month and is currently quoting at 26188.4, down 0.23% on the day. The volume in the stock stood at 5.56 lakh shares today, compared to the daily average of 4.44 lakh shares in last one month. The benchmark September futures contract for the stock is quoting at Rs 9139, down 0.61% on the day. Divis Laboratories Ltd jumped 50.52% in last one year as compared to a 8.14% slide in NIFTY and a 17.48% spurt in the Nifty Pharma index.The PE of the stock is 81.44 based on TTM earnings ending June 26.

2 months agoCapital Market - Live
Earnings
Earnings
Divis Laboratories Ltd consolidated sales up 8.80% on year in Q2FY2026, net profit jumped 20.11%

Divis Laboratories Ltd share price ticked higher by 2.76% to Rs 8056.65 after the company's net profit saw a strong growth of 20.11% to Rs 902.0 crore, while revenue from operations improved marginally 8.80% to Rs 3080.0 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 23.86 lakh crore, gaining 5.89%. It has marginally improved by 2.79% over last one week and rallied by 15.59% in last one month while the market capitalization of Divis Laboratories Ltd has edged up by 11.18% and 23.85% in the same period respectively. Profit before tax (PBT) of Divis Laboratories Ltd stood at Rs 1180.0 crore in Q2 FY26, rallying 60.98% year-on-year, and surging by 22.53% quarter-on-quarter. EBITDA came in at Rs 1191 crore, expanding by 95.25% YoY and jumping 52.89% sequentially. Total expenses marginally dropped 2.93% to Rs 1958.0 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 1503.0 crore, witnessing a sharp rise of 23.81% YoY, while employee benefits expense was at Rs 408.0 crore, rising by 7.09% YoY. For the TTM ended FY26, revenue from operations grew 12.82% to Rs 10560.0 crore, while net profit registered a growth of 17.21% to Rs 2568.0 crore, compared to previous TTM. EBITDA surged by 267600% to Rs 2934.0 crore, and PBT rose 16.19% to Rs 3388.0 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 2738.0 crore in FY26, as against Rs 1653.0 crore in FY25. Divis Laboratories Ltd soared by 22.06% in last one year, significantly outperforming the benchmark BSE Sensex which has slipped by 3.81% during the same period.

3 months agoCapital Market - Live
Spotlight
Spotlight
Divis Laboratories Ltd spurts 2.48%, gains for five straight sessions

Divis Laboratories Ltd rose for a fifth straight session today. The stock is quoting at Rs 8029, up 2.48% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.35% on the day, quoting at 24401.75. The Sensex is at 78214.53, up 0.37%. Divis Laboratories Ltd has added around 22.66% in last one month. Meanwhile, Nifty Pharma index of which Divis Laboratories Ltd is a constituent, has added around 5.81% in last one month and is currently quoting at 26346.05, up 1.14% on the day. The volume in the stock stood at 4.85 lakh shares today, compared to the daily average of 4.72 lakh shares in last one month. The benchmark August futures contract for the stock is quoting at Rs 8044.5, up 2.37% on the day. Divis Laboratories Ltd is up 26.21% in last one year as compared to a 0.67% fall in NIFTY and a 21.06% fall in the Nifty Pharma index.The PE of the stock is 78.18 based on TTM earnings ending March 26.

3 months agoCapital Market - Live
Corporate
Corporate
Divi's Laboratories announces leadership changes, with two executives retiring in 2026

Divi's Laboratories Limited informed the National Stock Exchange of India Limited and BSE Limited that L. Ramesh Babu and D. Madhu Babu will cease to be Senior Management Personnel, retiring from their positions as Vice President (Procurement) and Vice President (Projects) respectively, effective July 31, 2026.

3 months agoCapital Market - Live

Frequently asked questions

  1. The share price of DIVISLAB as on 16th November 2026 is ₹11080. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.

  2. The past returns of Divi's Laboratories Ltd (DIVISLAB) share are
    • Past 1 week: -0.15%
    • Past 1 month: 22.70%
    • Past 3 months: 30.74%
    • Past 6 months: 62.11%
    • Past 1 year: 69.98%
    • Past 3 years: 212.27%
    • Past 5 years: 128.33%

  3. The current dividend yield of Divi's Laboratories Ltd (DIVISLAB) is 0.27.

  4. Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Divi's Laboratories Ltd (DIVISLAB) is ₹294139.19 Cr as of 16th November 2026.

  5. The 52-week high of Divi's Laboratories Ltd (DIVISLAB) is ₹11824 and the 52-week low is ₹5647.50.

  6. The P/E (price-to-earnings) ratio of Divi's Laboratories Ltd (DIVISLAB) is 112.14. The P/B (price-to-book) ratio is 17.55.

  7. Divi's Laboratories Ltd (DIVISLAB) belongs to the Health Care sector & Labs & Life Sciences Services sub-sector.

  8. You can directly buy Divi's Laboratories Ltd (DIVISLAB) shares on Tickertape. Simply sign up, connect your demat account and place your order.